Advertisement

Sleep Complaints, Sleep and Breathing Disorders in Myotonic Dystrophy Type 2

  • Andrea RomigiEmail author
  • Michelangelo Maestri
  • Carmine Nicoletta
  • Giuseppe Vitrani
  • Marco Caccamo
  • Gabriele Siciliano
  • Enrica Bonanni
  • Diego Centonze
  • Alessandro Sanduzzi
Sleep (M Thorpy and M Billiard, Section Editors)
  • 95 Downloads
Part of the following topical collections:
  1. Topical Collection on Sleep

Abstract

Purpose of Review

To update the current knowledge concerning sleep complaints and breathing disorders in myotonic dystrophy type 2 (DM2) and to better understand if sleep and breathing symptoms may add a further clinical definition of DM2.

Recent Findings

Although DM2 has been poorly evaluated, the most relevant sleep disorders are sleep-disordered breathing (SDB) (37.5–66.7%) and restless legs syndrome (RLS) (50–60%). Excessive daytime somnolence (EDS) is not consistent with SDB, and a large percentage of patients with sleep complaints (58–69%) report pain. In addition, respiratory dysfunctions are reported in 6 to 15% of DM2 patients, albeit few data are available regarding pulmonary restriction, hypoventilation, and non-invasive ventilation (NIV).

Summary

SDB, RLS, and pain may contribute to sleep fragmentation and EDS in DM2. In addition, few studies report hypoventilation and pulmonary restriction, although there are no studies at all on NIV, except for limited clinical experiences. These findings suggest performing a careful pulmonary examination and NIV when required. Furthermore, sleep studies and respiratory evaluation should be recommended if OSA or respiratory muscle dysfunctions are suspected. A large polysomnographic study should be performed to clarify the link between sleep disorders, pain, and sleep disruption in DM2.

Keywords

Myotonic dystrophy type 2 Excessive daytime somnolence Sleep Sleep-disordered breathing Hypoventilation Fatigue Pain 

Notes

Compliance with Ethical Standards

Conflict of Interest

Andrea Romigi reports other from EISAI, personal fees from SANDOZ, personal fees from Fidia Farmaceutici, outside the submitted work. Giuseppe Vitrani received a personal fee from Fidia Farmaceutici outside the submitted work. Enrica Bonanni, Marco Caccamo, Diego Centonze, Michelangelo Maestri, Carmine Nicoletta, Alessandro Sanduzzi, and Gabriele Siciliano each declare no potential conflicts of interest.

Human and Animal Rights

The article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry. 2010;81:358–67.PubMedCrossRefGoogle Scholar
  2. 2.
    Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012;11:891–905.PubMedCrossRefGoogle Scholar
  3. 3.
    Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science. 1992;255:1253–5.Google Scholar
  4. 4.
    Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293:864–7.Google Scholar
  5. 5.
    • Wenninger S, Montagnese F, Schoser B. Core clinical phenotypes in myotonic dystrophies. Front Neurol. 2018;9:303 A comprehensive revision of clinical phenotypes of both DM1 and DM2. PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    LoRusso S, Weiner B, Arnold WD. Myotonic dystrophies: targeting therapies for multisystem disease. Neurotherapeutics. 2018;15:872–84.PubMedCrossRefGoogle Scholar
  7. 7.
    •• Montagnese F, Mondello S, Wenninger S, Kress W, Schoser B. Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2. J Neurol. 2017;264:2472–80 A detailed clinical chacterization of a large cohort of DM2 patients investigating the role of age and gender influencing DM2 phenotype. PubMedCrossRefGoogle Scholar
  8. 8.
    • Fermin AM, Afzal U, Culebras A. Sleep in neuromuscular diseases. Sleep Med Clin. 2016;11:53–64 A comprehensive review regarding the relationship between sleep disorders and neuromuscular disorders. PubMedCrossRefGoogle Scholar
  9. 9.
    Laberge L, Gagnon C, Dauvilliers Y. Daytime sleepiness and myotonic dystrophy. Curr Neurol Neurosci Rep. 2013;13:340.PubMedCrossRefGoogle Scholar
  10. 10.
    Bianchi MLE, Losurdo A, Di Blasi C, Santoro M, Masciullo M, Conte G, et al. Prevalence and clinical correlates of sleep disordered breathing in myotonic dystrophy types 1 and 2. Sleep Breath. 2014;18:579–89.PubMedCrossRefGoogle Scholar
  11. 11.
    Tieleman AA, Knoop H, van de Logt A-E, Bleijenberg G, van Engelen BGM, Overeem S. Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. J Neurol Neurosurg Psychiatry. 2010;81:963–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Romigi A, Albanese M, Placidi F, Izzi F, Liguori C, Marciani MG, et al. Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self-reported questionnaires. Eur J Neurol. 2014;21:929–34.Google Scholar
  13. 13.
    Lam EM, Shepard PW, St Louis EK, Dueffert LG, Slocumb N, McCarter SJ, et al. Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology. 2013;81:157–64.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Kohn NN, Faires JS, Rodman T. Unusual manifestations due to involvement of involuntary muscle in dystrophia myotonica. N Engl J Med. 1964;271:1179–83.PubMedCrossRefGoogle Scholar
  15. 15.
    Coccagna G, Mantovani M, Parchi C, Mironi F, Lugaresi E. Alveolar hypoventilation and hyperosmnia in myotonic dystrophy. J Neurol Neurosurg Psychiatry. 1975;38:977–84.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Coccagna G, Martinelli P, Lugaresi E. Sleep and alveolar hypoventilation in myotonic dystrophy. Acta Neurol Belg. 1982;82:185–94.PubMedGoogle Scholar
  17. 17.
    Romigi A, Albanese M, Liguori C, Placidi F, Marciani MG, Massa R. Sleep-wake cycle and daytime sleepiness in the myotonic dystrophies. J Neurodegener Dis. 2013;2013:692026.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Yu H, Laberge L, Jaussent I, Bayard S, Scholtz S, Raoul M, et al. Daytime sleepiness and REM sleep characteristics in myotonic dystrophy: a case-control study. Sleep. 2011;34:165–70.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Romigi A, Izzi F, Pisani V, Placidi F, Pisani LR, Marciani MG, et al. Sleep disorders in adult-onset myotonic dystrophy type 1: a controlled polysomnographic study. Eur J Neurol. 2011;18:1139–45.Google Scholar
  20. 20.
    Dauvilliers YA, Laberge L. Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation. Sleep Med Rev. 2012;16:539–45.PubMedCrossRefGoogle Scholar
  21. 21.
    Mah JK, Korngut L, Fiest KM, Dykeman J, Day LJ, Pringsheim T, et al. A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci. 2016;43:163–77.Google Scholar
  22. 22.
    Shepard P, Lam EM, St Louis EK, Dominik J. Sleep disturbances in myotonic dystrophy type 2. Eur Neurol. 2012;68:377–80.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Leonardis L, Blagus R, Dolenc GL. Sleep and breathing disorders in myotonic dystrophy type 2. Acta Neurol Scand. 2015;132:42–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Romigi A, Placidi F, Albanese M, Izzi F, Liguori C, Mercuri NB, et al. Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology. 2014;83:572–3.Google Scholar
  25. 25.
    • Romigi A, Franco V, Placidi F, Liguori C, Rastelli E, Vitrani G, et al. Comparative sleep disturbances in myotonic dystrophy types 1 and 2. Curr Neurol Neurosci Rep. 2018;18:102 The most recent comparative review regading sleep disoders in DM1 and DM2. PubMedCrossRefGoogle Scholar
  26. 26.
    Turner C, Hilton-Jones D. Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol. 2014;27:599–606.PubMedCrossRefGoogle Scholar
  27. 27.
    Harley HG, Brook JD, Rundle SA, Crow S, Reardon W, Buckler AJ, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature. 1992;355:545–6.Google Scholar
  28. 28.
    Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;68:799–808.CrossRefGoogle Scholar
  29. 29.
    • Meola G, Cardani R. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects. Neurol Sci. 2017;38:535–46 A clear clinical and genetic chacterization of DM2. PubMedCrossRefGoogle Scholar
  30. 30.
    Sansone VA. The dystrophic and nondystrophic myotonias. Continuum (Minneap, Minn). 2016;22:1889–915.Google Scholar
  31. 31.
    Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord. 2003;13:813–21.Google Scholar
  32. 32.
    Suominen T, Bachinski LL, Auvinen S, Hackman P, Baggerly KA, Angelini C, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet. 2011;19:776–82.Google Scholar
  33. 33.
    •• Vanacore N, Rastelli E, Antonini G, Bianchi MLE, Botta A, Bucci E, et al. An age-standardized prevalence estimate and a sex and age distribution of myotonic dystrophy types 1 and 2 in the Rome Province, Italy. Neuroepidemiology. 2016;46:191–7 The first age-standardized minimun prevalence and sex and age distribution study of both DM1 and DM2 in a large European general population. PubMedCrossRefGoogle Scholar
  34. 34.
    Grigg-Damberger MM, Wagner LK, Brown LK. Sleep hypoventilation in patients with neuromuscular diseases. Sleep Med Clin. 2012;7:667–87.CrossRefGoogle Scholar
  35. 35.
    • Boentert M, Wenninger S, Sansone VA. Respiratory involvement in neuromuscular disorders. Curr Opin Neurol. 2017;30:529–37 A recent review reagarding respiratoty involvement in neuroscular diseases. PubMedCrossRefGoogle Scholar
  36. 36.
    •• Poussel M, Thil C, Kaminsky P, Mercy M, Gomez E, Chaouat A, et al. Lack of correlation between the ventilatory response to CO2 and lung function impairment in myotonic dystrophy patients: evidence for a dysregulation at central level. Neuromuscul Disord. 2015;25:403–8 DM1 patients showed reduced ventilatory response to CO2 independent of lung function impairment and respiratory muscle weakness, suggesting a central cause of CO2 insensitivity. PubMedCrossRefGoogle Scholar
  37. 37.
    Mathieu J, Allard P, Potvin L, Prévost C, Bégin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology. 1999;52:1658–62.PubMedCrossRefGoogle Scholar
  38. 38.
    Poussel M, Kaminsky P, Renaud P, Laroppe J, Pruna L, Chenuel B. Supine changes in lung function correlate with chronic respiratory failure in myotonic dystrophy patients. Respir Physiol Neurobiol. 2014;193:43–51.PubMedCrossRefGoogle Scholar
  39. 39.
    •• Sansone VA, Gagnon C. Participants of the 207th ENMC workshop. 207th ENMC workshop on chronic respiratory insufficiency in myotonic dystrophies: management and implications for research, 27-29 June 2014, Naarden, The Netherlands. Neuromuscul Disord. 2015;25:432–42 A consensus conference regarding chronic respiratory involvement in mytonic dystrophies. The authors reported the sole experience of NIV in DM2. PubMedCrossRefGoogle Scholar
  40. 40.
    Pincherle A, Patruno V, Raimondi P, Moretti S, Dominese A, Martinelli-Boneschi F, et al. Sleep breathing disorders in 40 Italian patients with Myotonic dystrophy type 1. Neuromuscul Disord. 2012;22:219–24.Google Scholar
  41. 41.
    Gagnon C, Heatwole C, Hébert LJ, Hogrel J-Y, Laberge L, Leone M, et al. Report of the third outcome measures in myotonic dystrophy type 1 (OMMYD-3) international workshop Paris, France, June 8, 2015. J Neuromuscul Dis. 2018;5:523–37.Google Scholar
  42. 42.
    Bozovic I, Peric S, Pesovic J, Bjelica B, Brkusanin M, Basta I, et al. Myotonic dystrophy type 2 - data from the Serbian registry. J Neuromuscul Dis. 2018;5:461–9.Google Scholar
  43. 43.
    Bhat S, Sander HW, Grewal RP, Chokroverty S. Sleep disordered breathing and other sleep dysfunction in myotonic dystrophy type 2. Sleep Med. 2012;13:1207–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Banach M, Antczak J, Rola R. Association of peripheral neuropathy with sleep-related breathing disorders in myotonic dystrophies. Neuropsychiatr Dis Treat. 2017;13:133–40.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    American Academy of Sleep Medicine. International classification of sleep disorders. In: 3rd ed. Darien IL, editor. IL: American Academy of SleepMedicine; 2014; 53.Google Scholar
  46. 46.
    Laberge L, Gagnon C, Jean S, Mathieu J. Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability. J Neurol Neurosurg Psychiatry. 2005;76:1403–5.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283–95.PubMedCrossRefGoogle Scholar
  48. 48.
    George A, Schneider-Gold C, Zier S, Reiners K, Sommer C. Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol. 2004;61:1938–42.PubMedGoogle Scholar
  49. 49.
    Silvestri G, Bianchi MLE, Losurdo A, Della MG. Author response. Neurology. 2014;83:572–3.PubMedGoogle Scholar
  50. 50.
    Laberge L, Bégin P, Dauvilliers Y, Beaudry M, Laforte M, Jean S, et al. A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry. 2009;80:642–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Ciafaloni E, Mignot E, Sansone V, Hilbert JE, Lin L, Lin X, et al. The hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology. 2008;70:226–30.Google Scholar
  52. 52.
    •• Bonanni E, Carnicelli L, Crapanzano D, Maestri M, Simoncini C, Baldanzi S, et al. Disruption of sleep-wake continuum in myotonic dystrophy type 1: beyond conventional sleep staging. Neuromuscul Disord. 2018;28:414–21 A polysomnographic study regarding DM1 patients and cyclic alternating pattern analysis. The authors confirmed REM sleep dysregulation, sleep fragmentation, and nonREM alterations as expressed by slower delta power decline. PubMedCrossRefGoogle Scholar
  53. 53.
    Chokroverty S, Bhat S, Rosen D, Farheen A. REM behavior disorder in myotonic dystrophy type 2. Neurology. 2012;78:2004.PubMedCrossRefGoogle Scholar
  54. 54.
    Huang J, Zhang J, Lam SP, Li SX, Ho CKW, Lam V, et al. Amelioration of obstructive sleep apnea in REM sleep behavior disorder: implications for the neuromuscular control of OSA. Sleep. 2011;34:909–15.Google Scholar
  55. 55.
    Rye DB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep. 1997;20:757–88.PubMedCrossRefGoogle Scholar
  56. 56.
    Mills RJ, Young CA. A medical definition of fatigue in multiple sclerosis. QJM. 2008;101:49–60.PubMedCrossRefGoogle Scholar
  57. 57.
    • Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, et al. Patient-reported impact of symptoms in myotonic dystrophy type 2 (PRISM-2). Neurology. 2015;85:2136–46 A large survey regading DM2 burden as perceived by DM2 patients. PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    • Rakocevic Stojanovic V, Peric S, Paunic T, Pesovic J, Vujnic M, Peric M, et al. Quality of life in patients with myotonic dystrophy type 2. J Neurol Sci. 2016;365:158–61 Evaluation of the quality of life of DM2 by disease-specific scales, demonstrating that the most severe DM2 had similar low QoL as in DM1. PubMedCrossRefGoogle Scholar
  59. 59.
    Tieleman AA, den Broeder AA, van de Logt AE, van Engelen BGM. Strong association between myotonic dystrophy type 2 and autoimmune diseases. J Neurol Neurosurg Psychiatry. 2009;80:1293–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Rohleder N, Aringer M, Boentert M. Role of interleukin-6 in stress, sleep, and fatigue. Ann N Y Acad Sci. 2012;1261:88–96.PubMedCrossRefGoogle Scholar
  61. 61.
    Romigi A, Pierantozzi M, Izzi F, Desiato MT, Liguori C, Marchi A, et al. Restless legs syndrome and poliomyelitis: new evidences of an old observation? Front Neurol. 2015;6:23.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    •• Romigi A, Pierantozzi M, Placidi F, Evangelista E, Albanese M, Liguori C, et al. Restless legs syndrome and post polio syndrome: a case-control study. Eur J Neurol. 2015;22:472–8 The first case-control study showing high prevalence of restless legs syndrome in post-polio syndrome. PubMedCrossRefGoogle Scholar
  63. 63.
    Suokas KI, Haanpää M, Kautiainen H, Udd B, Hietaharju AJ. Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve. 2012;45:70–4.PubMedCrossRefGoogle Scholar
  64. 64.
    •• van Vliet J, Tieleman AA, Verrips A, Timmerman H, van Dongen RTM, van Engelen BGM, et al. Qualitative and quantitative aspects of pain in patients with myotonic dystrophy type 2. J Pain. 2018;19:920–30 Pain as a key clinical feature of DM2, as demonstrated by widespreadness of hyperalgesia in DM2. PubMedCrossRefGoogle Scholar
  65. 65.
    Peric M, Peric S, Rapajic N, Dobricic V, Savic-Pavicevic D, Nesic I, et al. Multidimensional aspects of pain in myotonic dystrophies. Acta Myol. 2015;34:126–32.PubMedPubMedCentralGoogle Scholar
  66. 66.
    Tieleman AA, Jenks KM, Kalkman JS, Borm G, van Engelen BGM. High disease impact of myotonic dystrophy type 2 on physical and mental functioning. J Neurol. 2011;258:1820–6.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Moshourab R, Palada V, Grunwald S, Grieben U, Lewin GR, Spuler S. A molecular signature of myalgia in myotonic dystrophy 2. EBioMedicine. 2016;7:205–11.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Andrea Romigi
    • 1
    Email author
  • Michelangelo Maestri
    • 2
  • Carmine Nicoletta
    • 3
  • Giuseppe Vitrani
    • 1
  • Marco Caccamo
    • 1
  • Gabriele Siciliano
    • 2
  • Enrica Bonanni
    • 2
  • Diego Centonze
    • 1
  • Alessandro Sanduzzi
    • 3
  1. 1.IRCCS NeuromedSleep Medicine CenterPozzilliItaly
  2. 2.Department of Clinical and Experimental Medicine, Neurology UnitUniversity of PisaPisaItaly
  3. 3.Department of Clinical Medicine and Surgery, Section of Respiratory DiseasesUniversity of Naples Federico IINaplesItaly

Personalised recommendations